Astellas Venture Management is a venture capital firm in Menlo Park that prefers to invest in companies within the biotechnology sector. Founded 1999 in Menlo Park, California, the firm invests in early stage ventures, late stage ventures, and private equity. The notable investment portfolio of Astellas Venture Management includes TScan Therapeutics, Heartseed, CODA Biotherapeutics, Oncorus, Cleave Therapeutics, Twentyeight-Seven Therapeutics, Effector Therapeutics, and Oncorus. As of January 2020, Astellas Venture Management has made 41 investments and 9 exits. Their most recent investment was on Jan 10, 2020, when TScan Therapeutics raised $35M.
Timeline
Founded
Funded Companies
A company developing therapies for the treatment of cancer and immune disorders
A biopharmaceutical company focused on the discovery and development of epigenetic medicines to treat cancer and other disease
A biopharmaceutical company that develops drugs for the treatment of cardiovascular diseases, endocrine and other metabolic disorders
A company dedicated on the discovery and development of small molecule therapeutics to treat cancer
A company developing biologically active compounds and drug candidates
A biotechnology company developing peptides and antibodies for inflammation and autoimmunity
A biotechnology company that develops RNA interference therapeutics
Twentyeight-Seven is a biomedical startup with a passion for cutting-edge life saving technology.
Cleave Biosciences is a Burlingame, California-based company.
People
Takashi Futami
Associate Investment Director
Ken Shimokawa
Senior Investment Director
Makoto Ohori
Investment Director
Sakae Asanuma
President & Chief Executive Officer
Takatoshi Soga
Associate Investment Director
Taro Masunaga
Investment Director
Further reading
Documentaries, videos and podcasts
Companies
Cleave Therapeutics
Twentyeight-Seven Therapeutics
CODA Biotherapeutics
Effector Therapeutics
Heartseed
Oncorus
TScan Therapeutics
